Skip to main content

Table 3 Tumor response by treatment free-interval in patients treated as second-line

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Tumor Response

Treatment free-interval (N = 20)

 

< 3 months

3-6 months

> 6 months

 

No.

(%)

No.

(%)

No.

(%)

Complete response

1

(7.7)

0

(0)

0

(0)

Partial response

5

(38.5)

1

(33)

3

(75)

Stable disease

2

(15.4)

2

(67)

1

(25)

Progressive disease

5

(38.5)

0

(0)

0

(0)

Total

13

(100)

3

(100)

4

(100)